Evidence for the putative cannabinoid receptor (GPR55)-mediated inhibitory effects on intestinal contractility in mice

Pharmacology

Volumn 90, Issue 1-2, 2012, Pages 55-65

  Ross, Gracious R ^a   Lichtman, Aron ^a   Dewey, William L ^a   Akbarali, Hamid I ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Cannabinoid receptors; Colon contractility; GPR55; Ileum; JWH015; O 1602

Indexed keywords

2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; ACETYLCHOLINE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 55; O 1602; POTASSIUM ION; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON MOTILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ELECTROSTIMULATION; HYPOTHESIS; ILEUM CONTRACTION; INTESTINE CONTRACTION; KNOCKOUT MOUSE; MALE; MOUSE; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; PRESYNAPTIC INHIBITION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; SMOOTH MUSCLE RELAXATION; WILD TYPE;

ACETYLCHOLINE; ANIMALS; CANNABINOID RECEPTOR AGONISTS; CANNABINOIDS; COLON; CYCLOHEXANES; GASTROINTESTINAL MOTILITY; MALE; MICE; MICE, KNOCKOUT; MUSCLE CONTRACTION; MUSCLE, SMOOTH; RECEPTORS, CANNABINOID; RESORCINOLS;

EID: 84863112729     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000339076     Document Type: Article

References (37)

1. Dewey WL: Cannabinoid pharmacology. Pharmacol Rev 1986; 38:151-178.
2. Mechoulam R, Gaoni Y: Hashish. IV. The isolation and structure of cannabinolic can-nabidiolic and cannabigerolic acids. Tetrahedron 1965; 21:1223-1229.
3. Wagner JA, Varga K, Jarai Z, Kunos G: Mes-enteric vasodilation mediated by endothelial anandamide receptors. Hypertension 1999; 33:429-434.
4. Jarai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, Zimmer AM, Bonner TI, Buckley NE, Mezey E, Razdan RK, Zimmer A, Kunos G: Cannabinoid-in-duced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA 1999; 96: 14136-14141.
5. Sawzdargo M, Nguyen T, Lee D, Lynch K, Cheng R, Heng H, George S, O'Dowd B: Identification and cloning of three novel human G-protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res Mol Brain Res 1999; 64: 193-198.
6. Moriconi A, Cerbara I, Maccarrone M, Topai A: GPR55: Current knowledge and future perspectives of a purported 'type-3' cannabi-noid receptor. Curr Med Chem 2010; 17: 1411-1429.
7. Johns DG, Behm DJ, Walker DJ, Ao Z, Shap-land EM, Daniels DA, Riddick M, Dowell S, Staton PC, Green P, Shabon U, Bao W, Aiyar N, Yue TL, Brown AJ, Morrison AD, Douglas SA: The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol 2007; 152:825-831.
8. Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson N, Leonova J, Elebring T, Nils-son K, Drmota T, Greasley P: The or phan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007; 152:1092.
9. Whyte LS, Ryberg E, Sims NA, Ridge SA, Mackie K, Greasley PJ, Ross RA, Rogers MJ: The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci USA 2009; 106:16511-16516.
10. Lauckner J, Jensen J, Chen H, Lu H, Hille B, Mackie K: GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits m current. Proc Natl Acad Sci USA 2008; 105:2699.
11. Martin BR, Wiley JL: Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain. J Support Oncol 2004; 2: 305-314.
12. Izzo AA, Sharkey KA: Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther 2010; 126:21-38.
13. Brown AJ: Novel cannabinoid receptors. Br J Pharmacol 2007; 152: 567-575.
14. Ito J, Ito M, Nambu H, Fujikawa T, Tanaka K, Iwaasa H, Tokita S: Anatomical and histo-logical profiling of orphan G-protein-cou-pled receptor expression in gastrointestinal tract of C57BL/6J mice. Cell Tissue Res 2009; 338:257-269.
15. Lin XH, Yuece B, Li YY, Feng YJ, Feng JY, Yu LY, Li K, Li YN, Storr M: A novel CB receptor GPR55 and its ligands are involved in regulation of gut movement in rodents. Neurogas-troenterol Motil 2011; 23: 862,e342.
16. Schicho R, Bashashati M, Bawa M, McHugh D, Saur D, Hu HM, Zimmer A, Lutz B, Mackie K, Bradshaw HB, McCafferty DM, Sharkey KA, Storr M: The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. In-flamm Bowel Dis 2011; 17:1651-1664.
17. Heinemann A, Shahbazian A, Holzer P: Cannabinoid inhibition of guinea-pig intestinal peristalsis via inhibition of excitatory and activation of inhibitory neural pathways. Neuropharmacology 1999; 38:1289-1297.
18. 9-tetrahydrocannabinol on cholinergic transmission in the myenteric plexus of the guinea pig. Can J Physiol Pharmacol 1978; 56: 968-975.
19. Offertaler L, Mo FM, Batkai S, Liu J, Begg M, Razdan RK, Martin BR, Bukoski RD, Kunos G: Selective ligands and cellular effectors of a G-protein-coupled endothelial cannabi-noid receptor. Mol Pharmacol 2003; 63:699-705.
20. Schuelert N, McDougall JJ: The abnormal cannabidiol analogue O-1602 reduces noci-ception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55. Neurosci Lett 2011; 500:72-76.
21. McHugh D, Hu SS, Rimmerman N, Juknat A, Vogel Z, Walker JM, Bradshaw HB: N-ar-achidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci 2010; 11: 44.
22. + channels. J Pharmacol Exp Ther 2009; 328: 351-361.
23. Griffin G, Fernando SR, Ross RA, McKay NG, Ashford ML, Shire D, Huffman JW, Yu S, Lainton JA, Pertwee RG: Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. Eur J Pharmacol 1997; 339: 53-61.
24. Munro S, Thomas K, Abu-Shaar M: Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365:61-65.
25. Matsuda L, Lolait S, Brownstein M, Young A, Bonner T: Structure of a cannabinoid receptor and functional expression of the cloned CDNA. Nature 1990; 346: 561-564.
26. Begg M, Pacher P, Bátkai S, Osei-Hyiaman D, Offertáler L, Mo F, Liu J, Kunos G: Evidence for novel cannabinoid receptors. Pharmacol Ther 2005; 106: 133-145.
27. Ross RA: The enigmatic pharmacology of GPR55. Trends Pharmacol Sci 2009; 30:156-163.
28. Hiley C, Kaup S: GPR55 and the vascular receptors for cannabinoids. Br J Pharmacol 2007; 152:559.
29. Sawzdargo M, George SR, Nguyen T, Xu S, Kolakowski LF, O'Dowd BF: A cluster of four novel human G-protein-coupled receptor genes occurring in close proximity to CD22 gene on chromosome 19q13.1. Biochem Bio-phys Res Commun 1997; 239: 543-547.
30. Strausberg RL, Feingold EA, Grouse LH, Derge JG, Klausner RD, Collins FS, Wagner L, Shenmen CM, Schuler GD, Altschul SF, Zeeberg B, Buetow KH, Schaefer CF, Bhat NK, Hopkins RF, Jordan H, Moore T, Max SI, Wang J, Hsieh F, Diatchenko L, Marusi-na K, Farmer AA, Rubin GM, Hong L, Sta-pleton M, Soares MB, Bonaldo MF, Casa-vant TL, Scheetz TE, Brownstein MJ, Usdin TB, Toshiyuki S, Carninci P, Prange C, Raha SS, Loquellano NA, Peters GJ, Abramson RD, Mullahy SJ, Bosak SA, McE-wan PJ, McKernan KJ, Malek JA, Gunaratne PH, Richards S, Worley KC, Hale S, Garcia AM, Gay LJ, Hulyk SW, Villalon DK, Muzny DM, Sodergren EJ, Lu X, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Ro-drigues S, Sanchez A, Whiting M, Young AC, Shevchenko Y, Bouffard GG, Blakesley RW, Touchman JW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Krzywinski MI, Skalska U, Smailus DE, Schnerch A, Schein JE, Jones SJ, Marra MA: Generation and initial analysis of more than 15,000 full-length human and mouse CDNA sequences. Proc Natl Acad Sci USA 2002; 99: 16899-16903.
31. Kapur A, Zhao P, Sharir H, Bai Y, Caron MG, Barak LS, Abood ME: Atypical responsiveness of the orphan receptor GPR55 to can-nabinoid ligands. J Biol Chem 2009; 284: 29817-29827.
32. Corda D, Iurisci C, Berrie C: Biological activities and metabolism of the lysophos-phoinositides and glycerophosphoinositols. Biochim Biophys Acta 2002; 1582:52-69.
33. Borrelli F, Izzo AA: Role of acylethanol-amides in the gastrointestinal tract with special reference to food intake and energy balance. Best Pract Res Clin Endocrinol Metab 2009; 23: 33-49.
34. Mathison R, Ho W, Pittman QJ, Davison JS, Sharkey KA: Effects of cannabinoid re-ceptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated rats. Br J Pharmacol 2004; 142: 1247-1254.
35. Capasso R, Borrelli F, Cascio MG, Aviello G, Huben K, Zjawiony JK, Marini P, Romano B, Di Marzo V, Capasso F, Izzo AA: Inhibitory effect of Salvinorin A, from Salvia divino-rum, on ileitis-induced hypermotility: crosstalk between?-opioid and cannabinoid CB(1) receptors. Br J Pharmacol 2008; 155: 681-689.
36. Duncan M, Mouihate A, Mackie K, Keenan CM, Buckley NE, Davison JS, Patel KD, Pitt-man QJ, Sharkey KA: Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipo-polysaccharide-treated rats. Am J Physiol Gastrointest Liver Physiol 2008; 295:G78-G87.
37. Mule F, Amato A, Baldassano S, Serio R: Involvement of CB1 and CB2 receptors in the modulation of cholinergic neurotransmis-sion in mouse gastric preparations. Pharmacol Res 2007; 56: 185-192.